Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Todd N who wrote (4515)	6/17/1998 2:15:00 PM
From: John Metcalf	of 6136

Todd, Monsanto's G.D.Searle website has information on each stage of the drug development process, along with a drug development "game", or simulation. However -- data on how many drugs progress to the next phase of clinical trials is skewed by companies that take compounds with very little promise into the next round in order to keep the pot boiling while they look for something else. In this case, Agouron believes that efficacy is equal to the existing treatment without having to administer toxic levels of drug. The clinical rationale makes sense, and may be better when drug is given to people who are not in advanced stages of cancer where neovascularization has already occurred.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next